JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Geisbrecht, B. V.
Right arrow Articles by Gould, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geisbrecht, B. V.
Right arrow Articles by Gould, S. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 36, 25814-25820, September 3, 1999


The Mouse Gene PDCR Encodes a Peroxisomal Delta 2,Delta 4-Dienoyl-CoA Reductase*

Brian V. GeisbrechtDagger §, Xiquan Liang§, James C. MorrellDagger , Horst Schulz, and Stephen J. GouldDagger parallel

From the Dagger  Department of Biological Chemistry, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 and the  Department of Chemistry, City College, City University of New York, New York, New York 10031

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Here we describe the identification and characterization of a novel mouse gene, PDCR, that encodes a peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase. The mouse PDCR cDNA contains an 892-base pair open reading frame and is predicted to encode a 292-amino acid protein with a deduced molecular mass of 31,298 Da that terminates in a consensus type-1 peroxisomal targeting signal. Purified recombinant PDCR protein was generated from Escherichia coli and catalyzed the NADPH-dependent reduction of Delta 2-trans,Delta 4-trans-decadienoyl-CoA with a specific activity of 20 units/mg. Enzymatic characterization followed by high pressure liquid chromatography analysis of the products revealed that PDCR converted Delta 2-trans,Delta 4-trans-decadienoyl-CoA to a Delta 3-enoyl-CoA but not to a Delta 2-enoyl-CoA. Kinetic analyses demonstrated that PDCR is active on a broad range of Delta 2,Delta 4-dienoyl-CoAs. Although the observed substrate preference was to Delta 2-trans,Delta 4-trans-decadienoyl-CoA, PDCR was also active on a C22 substrate with multiple unsaturations, a result consistent with the role of peroxisomes in the oxidation of complex, very long chain, polyunsaturated fatty acids. The presence of a type-1 peroxisomal targeting signal Ala-Lys-Leu-COOH at the C terminus of PDCR suggested that this protein may be peroxisomal. We observed that tagged PDCR was efficiently transported to the peroxisome lumen in normal human fibroblasts but not in cells derived from a Zellweger syndrome patient with a specific defect in peroxisomal matrix protein import. We conclude that this protein resides within the peroxisome matrix and therefore represents the first mammalian peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase to be characterized at the molecular level.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mammalian peroxisomes contain multiple overlapping and complementary fatty acid beta -oxidation pathways that are able to metabolize a variety of different substrates, including saturated long and very long chain fatty acids, branched chain fatty acids, and dicarboxylic fatty acids. In addition, peroxisomes are able to degrade a variety of unsaturated fatty acids and thus must contain auxiliary enzymes such as Delta 3,Delta 2-enoyl-CoA isomerase, Delta 3,5,Delta 2,4-dienoyl-CoA isomerase, and Delta 2,Delta 4-dienoyl-CoA reductase (1). The oxidation of fatty acids with an unsaturation at an even positioned carbon eventually leads to formation of a Delta 2,Delta 4-dienoyl-CoA, which cannot be oxidized by beta -oxidation. Instead, the further oxidation of Delta 2,Delta 4-dienoyl-CoAs requires the successive action of Delta 2,Delta 4-dienoyl-CoA reductase to generate a Delta 3-enoyl-CoA, and Delta 3,Delta 2-enoyl-CoA isomerase to convert this intermediate to a Delta 2-enoyl-CoA that can re-enter the beta -oxidation spiral (see Fig. 1) (2). The oxidation of fatty acids with pre-existing unsaturations at odd-positioned carbons would appear to be even simpler, with one round of beta -oxidation converting the Delta 2,Delta 5-dienoyl-CoA to a Delta 3-enoyl-CoA and Delta 3,Delta 2-enoyl-CoA isomerase converting this to a Delta 2-enoyl-CoA substrate for further oxidation (see Fig. 1) (3). However, studies have established that there also exists a Delta 2,Delta 4-dienoyl-CoA reductase-dependent pathway for returning Delta 2,Delta 5-dienoyl-CoAs to the core spiral (Fig. 1) (4, 5). Thus, Delta 2,Delta 4-dienoyl-CoA reductases appear to play important roles in the oxidation of virtually all unsaturated fatty acids.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   Enzymatic steps specific for unsaturated fatty acid metabolism. beta -Oxidation of unsaturated fatty acids with double bonds at even-numbered carbons yields Delta 2,Delta 4-dienoyl-CoAs, which are metabolized as shown at left (2). Delta 2,Delta 5-Dienoyl-CoAs arising from beta -oxidation of unsaturated fatty acids with double bonds extending from odd-numbered carbons can return to the core spiral through both hydratase/isomerase-pathway (center) (3) and the reductase-dependent (right) shunt (4). Note that Delta 2,Delta 4-dienoyl-CoA reductase-catalyzed reactions are involved in the metabolism of both dienoyl-CoA species.

Recent studies have identified mammalian genes that encode the peroxisomal Delta 3,Delta 2-enoyl-CoA isomerase (6) and Delta 3,5,Delta 2,4-dienoyl-CoA isomerase (7), but the structural basis for peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase remains to be determined. However, genes encoding mammalian mitochondrial Delta 2,Delta 4-dienoyl-CoA reductases have been identified in both rat and humans (8, 9), and it is formally possible that the peroxisomal reductase mRNA could be generated from the same gene as the mitochondrial enzyme. In fact, such a mechanism is used to generate both peroxisomal and mitochondrial forms of Delta 3,5,Delta 2,4-dienoyl-CoA isomerase (7). Nonetheless, another possibility is that the peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase is encoded by a distinct gene that has yet to be recognized. Here we report the identification and characterization of a novel mouse gene, PDCR, and show that it encodes a peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning and Sequencing the Mus musculus PDCR Gene-- All sequence searches were performed using algorithms and data bases available at the National Center for Biotechnology Information web site. Mammalian homologues of the putative Caenorhabditis elegans peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase (F53C11.3) were identified by TBLASTN searches of the human and mouse expressed sequence tag data bases. Two cDNA clones from the IMAGE consortium (1924380 and 1888282) corresponded to the mouse ESTs1 AI316477 and AI286384 (GenBankTM accession numbers) and appeared to contain the full-length open reading frame of murine PDCR cDNAs. This was determined by the ability of these ESTs to encode proteins that (i) shared significant sequence similarities over the N terminus of F53C11.3 and yeast Sps19p and (ii) contained an appropriately positioned ATG codon with a good match to the Kozak consensus for high efficiency translation initiation (10, 11). These two clones were obtained from Genome Systems (St. Louis, MO), and the clone with the longer 5'-untranslated region (1924380) was sequenced in its entirety on both strands. Amino acid sequence alignments were performed with DNASTAR MegAlign software (Madison, WI) using the PAM250 substitution matrix.

Plasmids-- The Escherichia coli strain DH10B was used for the maintenance and amplification of all plasmids (12). All polymerase chain reactions were performed with a low error rate mixture of polymerases (Expand; Roche Molecular Biochemicals). A full-length form of the mouse PDCR open reading frame was generated by polymerase chain reaction using the cDNA clone 1888282 as a template and the oligonucleotides MmPDCR.5 (5'-GAAGTCGACCATGGCCCAGCCGCCGCCCGACGTTG-3') and MmPDCR.3 (5'-GAACGCGGCCGCGAATGCCTTTAATCCCAG-3') as primers. These oligonucleotides append SalI and NotI sites (underlined) at the 5' and 3' ends of the mouse PDCR open reading frame, respectively. The product of this polymerase chain reaction was digested with SalI and NotI and subcloned into the corresponding sites of pT7-His6. pT7-His6 is a modified form of pET28A (Novagen, Inc.) that contains XhoI and SalI sites in place of the NheI-HindIII fragment found in the parental vector. The sequence of the mouse PDCR open reading frame in pT7-His6 was confirmed by automated fluorescent sequencing, and the resulting plasmid was denoted pT7-His6-PDCR. This plasmid allows for T7-driven expression of a form of mouse PDCR bearing an N-terminal hexahistidinyl extension in the E. coli strain BL21(DE3) (Novagen). To generate the N-terminal c-myc-tagged form of the mouse PDCR open reading frame, the SalI-NotI insert of pT7-His6-PDCR was excised and subcloned into XhoI and NotI sites of pcDNA3-Nmyc (13). This plasmid allows for constitutive expression of an N-terminally c-myc-tagged form of mouse PDCR in mammalian cells.

Purification of Enzymes-- The E. coli strain BL21(DE3) was chosen for high level heterologous expression of the His6-PDCR protein. Specifically, several colonies from a plate of freshly transformed BL21(DE3) cells harboring the plasmid pT7-His6-PDCR were used to inoculate a 50-ml preculture of LB medium supplemented with 1% glucose and 25 µg/ml kanamycin sulfate. This preculture was grown 12 h at 30 °C with vigorous shaking (300 rpm), at which time 20 ml of the preculture were used to inoculate 500 ml of 2YT medium supplemented with 25 µg/ml kanamycin sulfate. This culture was grown with vigorous shaking for approximately 7 h at 18 °C until the A600 was approximately 0.4, at which time induction of protein expression was begun by the addition of isopropyl-beta -D-galactothiopyranoside to a final concentration of 1 mM. The induced culture was grown for an additional 18 h under the same conditions. The induced cells were harvested at 5,000 × g for 10 min at 4 °C at the end of this period.

The induced cells were resuspended in 50 ml of binding buffer (20 mM sodium-Pi (pH 7.8), 500 mM sodium chloride, and 5 mM benzamidine HCl) with 5 mM 2-mercaptoethanol, and the cells were lysed by sonication (14). Following cell lysis, a clarified extract was prepared by centrifuging the sonicate at 25,000 × g for 30 min at 4 °C. This extract (50 ml) was diluted to 150 ml with binding buffer and was applied at 1.5 ml/min to a 2-ml bed of Chelating Sepharose Fast Flow (Amersham Pharmacia Biotech) that was previously charged with nickel (II) chloride and equilibrated in binding buffer at 18 °C. After the entire extract was applied, the resin was washed sequentially with 50 bed volumes of binding buffer at pH 7.8 followed by 50 bed volumes of binding buffer at pH 6.0.

An imidazole step gradient in binding buffer at pH 6.0 was chosen to elute the bound proteins. Specifically, 2.5 column volumes of buffers containing imidazole at 50, 250, 350, and 500 mM were applied sequentially to the resin, and the individual eluents were collected. Proportional amounts of each fraction were analyzed by 15% SDS-polyacrylamide gel electrophoresis for the presence and purity of His6-PDCR (apparent Mr = 33,000). Fractions containing highly purified His6-PDCR (>95%) were removed, 2-mercaptoethanol was added to 5 mM final concentration, and the protein in each fraction was precipitated for storage by adding solid ammonium sulfate to 0.4 mg/ml. The purified, precipitated protein was collected by centrifugation and stored under buffer at -70 °C until needed.

Delta 2-Enoyl-CoA hydratase (crotonase) from bovine liver (15) and Delta 3,Delta 2-enoyl-CoA isomerase from rat liver mitochondria (16) were purified as described.

Analytical Methods and Substrate Synthesis-- All protein determinations were done by the Bradford method (Bio-Rad) using bovine serum albumin as a standard. Kinetic parameters (apparent Vmax and Km) were obtained by nonlinear curve fitting using the Sigma plot program. One unit of enzyme activity is defined as the amount of enzyme that converts 1 µmol of substrate to product per min. The assay of Delta 2,Delta 4-dienoyl-CoA reductase was based on the substrate-dependent oxidation of NADPH as described by Kunau and Dommes (2). Acyl-CoA thioesters were analyzed or purified by reverse-phase HPLC on a Waters µBondapak C18 column (30 cm × 3.9 mm) attached to a Waters gradient HPLC system. The absorbance of the effluent was monitored at 254 nm. Separation of different acyl-CoA thioesters was achieved by linearly increasing the acetonitrile/H2O (9:1 v/v) content of the 50 mM ammonium-Pi buffer (pH 5.5) from 20 to 50% at a flow rate of 2 ml/min. Delta 2-trans,Delta 4-trans-decadienoyl-CoA (17), Delta 2-trans,Delta 4-trans-hexadienoyl-CoA (18), and Delta 2-trans,Delta 4,Delta 7,Delta 10,Delta 13,Delta 16,Delta 19-cis-docosaheptaenoyl-CoA (18) were prepared as described.

Cell Culture, Transfections, and Immunofluorescence-- Methods for the culture and transfection of human skin fibroblasts have been described (19). The normal human fibroblast cell line GM5756 was purchased from the Coriell Cell Repository (Vineland, NJ). The pex10-deficient Zellweger syndrome cell line, PBD100, has been described (20). Methods for indirect immunofluorescence microscopy were performed as described (19). Standard immunofluorescence conditions involved fixing the cells in 3.7% formaldehyde/phosphate-buffered saline for 15 min and then permeabilizing all cellular membranes in 1% Triton X-100/phosphate-buffered saline for 5 min. For differential permeabilization experiments, the cells were fixed identically but permeabilized with 25 µg/ml digitonin for 2 min only.

The tissue culture supernatant from mouse hybridoma line 1-9E10 (Roche Molecular Biochemicals) was used as the source of the monoclonal anti-c-myc antibody. Guinea pig polyclonal anti-PMP70 antibodies were raised against a synthetic peptide corresponding to the C-terminal 18 amino acids of human PMP70 (21). Affinity purified, polyclonal sheep antibodies recognizing human catalase were purchased from The Binding Site (San Diego, CA) and were used according to the manufacturer's suggestions. Affinity purified fluorescein anti-mouse and anti-sheep and Texas Red anti-guinea pig secondary antibodies were obtained from Kirkegaard and Perry Laboratories (Gaithersburg, MD) and were used according to the manufacturer's suggestions.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Identification of a Murine Homologue of Saccharomyces cerevisiae Sps19p-- Mammalian peroxisomes are capable of oxidizing unsaturated fatty acids, and this process requires the enzymatic activity of Delta 2,Delta 4-dienoyl-CoA reductase. Although this activity has been detected in purified peroxisomes from mammalian sources (22-24), the purification of this enzyme has proved difficult and has limited detailed mechanistic and molecular studies of mammalian peroxisomal beta -oxidation. To understand the structural basis for mammalian peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase activity and to provide material for mechanistic studies of this enzyme, we initiated a computer-based search for genes that might encode such an enzyme.

We attempted to identify the mammalian peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase gene by searching for mammalian genes that were capable of encoding proteins with significant sequence similarity to yeast peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase, Sps19p (25). However, our searches using the Sps19p sequence as a BLAST query versus the data base of expressed sequence tags identified only ESTs corresponding to the previously identified mammalian mitochondrial Delta 2,Delta 4-dienoyl-CoA reductase gene. Therefore, we altered our search strategy and restricted our search to the recently completed C. elegans genome sequence. Three putative Delta 2,Delta 4-dienoyl-CoA reductase genes were identified in C. elegans, and the sequences of their deduced products (C. elegans proteins T05C12.3, W01C9.4, and F53C11.3) were examined. These three proteins were all highly similar to Sps19p, with BLAST e values of e-27 to e-28. However, one of these, F53C11.3, contained a match to the consensus type-1 peroxisomal targeting signal, Ser-Lys-Leu-COOH (26), at its C terminus. The presence of the type-1 peroxisomal targeting signal indicated that F53C11.3 might represent the peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase of C. elegans, and we used the F53C11.3 sequence to rescan the data bases of human and murine expressed sequence tags. Once again, the majority of ESTs we identified corresponded to the previously characterized mammalian mitochondrial Delta 2,Delta 4-dienoyl-CoA reductases. However, we also identified expressed sequence tags representing a second gene (a gene we have designated PDCR) that also shared significant similarity to F53C11.3.

Two murine ESTs encoded proteins that shared sequence similarity to the N terminus of both F53C11.3 and yeast Sps19p and the corresponding cDNA clones were obtained and characterized. Sequence analysis of the longer PDCR cDNA clone revealed the presence of a 2048-base pair cDNA containing a 5'-untranslated region of 121 base pairs, an 876-base pair open reading frame, and a 1451-base pair 3'-untranslated region (Fig. 2). The sequence of the PDCR open reading frame was confirmed by sequencing the second PDCR cDNA clone, which differed only in that it had a slightly shorter 5'-untranslated region. The deduced product of the PDCR gene is 292 amino acids long, has a predicted molecular mass of 31,298 Da, and has a pI of 9.4. Like Sps19p and F53C11.3, murine PDCR terminates in a match to the consensus type-1 peroxisomal targeting signal (26), Ala-Lys-Leu-COOH. Furthermore, an amino acid alignment between mouse PDCR, C. elegans F53C11.3, and S. cerevisiae Sps19p demonstrates that these proteins share extensive sequence similarities across their lengths (Fig. 3), with mouse PDCR showing 32 and 41% identity to the C. elegans and S. cerevisiae proteins, respectively.


View larger version (79K):
[in this window]
[in a new window]
 
Fig. 2.   Identification of a murine homologue of S. cerevisiae Sps19p. The nucleotide sequence of the murine PDCR cDNA is shown along with the deduced translation of the 876-base pair open reading frame contained therein. The deduced PDCR protein is basic (pI = 9.4), has a predicted subunit weight of 31,298, and terminates in the nearly consensus type-1 peroxisomal targeting signal Ala-Lys-Leu-COOH (underlined).


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 3.   Amino acid alignment of mouse PDCR with putative C. elegans and S. cerevisiae homologues. Clustal amino acid alignment of mouse PDCR with the hypothetical C. elegans protein F53C11.3 and S. cerevisiae Sps19p is shown. Residues that are conserved in all three sequences are shown as white letters on a black background.

Mouse PDCR Encodes a Delta 2,Delta 4-Dienoyl-CoA Reductase-- To test the hypothesis that mouse PDCR encoded a protein with Delta 2,Delta 4-dienoyl-CoA reductase activity, we subcloned the entire mouse PDCR open reading frame into the prokaryotic expression vector pT7-His6, expressed the His6-PDCR protein in E. coli, and purified the soluble, recombinant enzyme by immobilized metal ion affinity chromatography (Fig. 4). Analysis of the purified protein by SDS-polyacrylamide gel electrophoresis demonstrated that the protein was greater than 95% pure.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 4.   Purification of soluble, recombinant His6-PDCR by immobilized metal ion affinity chromatography. Hexahistidinyl-tagged PDCR was expressed and purified from E. coli by immobilized metal ion affinity chromatography. Chromatography was carried out as described under "Experimental Procedures," and proportional amounts of the following samples were analyzed by 15% SDS-polyacrylamide gel electrophoresis: M, molecular mass markers (indicated); L, clarified cell lysate; W, pH 7.8 and pH 6.0 column washes (combined); 50, 250, 350, and 500, imidazole concentration (in mM) in step gradient column eluents. The position of His6-PDCR is shown.

As a first assessment of the enzymatic activity of recombinant PDCR, we employed a spectrophotometric method to monitor changes in the absorbance spectrum of Delta 2-trans,Delta 4-trans-decadienoyl-CoA following the addition of PDCR (Fig. 5). The characteristic spectrum of a Delta 2,Delta 4-dienoyl-CoA is shown in Fig. 5, spectrum 1, with major absorbance bands centered near 260 and 300 nm that are attributable to the coenzyme A and dienoyl thioester moieties, respectively. Addition of purified PDCR to the assay mixture resulted in the disappearance of the dienoyl thioester chromophore at 300 nm and a decrease in absorbance at 340 nm that reflects the oxidation of NADPH (Fig. 5, spectra 2-4). This result demonstrated that recombinant, purified mouse PDCR has intrinsic Delta 2,Delta 4-dienoyl-CoA reductase activity.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 5.   Mouse PDCR is a Delta 2,Delta 4-dienoyl-CoA reductase. Spectral changes associated with the reduction of Delta 2-trans,Delta 4-trans-decadienoyl-CoA by NADPH in the presence of purified PDCR. Spectrum 1, Delta 2-trans,Delta 4-trans-decadienoyl-CoA (15 µM in 60 mM potassium-Pi (pH 7.4), 0.1 mM NADPH). The reference sample contained 60 mM potassium-Pi (pH 7.4) with 0.1 mM NADPH. Spectra 2-4, 5 s, 30 s, and 1 min after starting the reaction by the addition of purified PDCR (0.44 µg/ml) to the reaction sample.

It has previously been observed that the enzyme catalyzed reduction of Delta 2-trans,Delta 4-trans-dienoyl-CoAs can result in either Delta 3-enoyl-CoAs (25, 27, 28) or Delta 2-enoyl-CoAs (27, 29). Thus, the PDCR-catalyzed reduction of Delta 2-trans,Delta 4-trans-decadienoyl-CoA shown in Fig. 5 was expected to yield either Delta 3-decenoyl-CoA, as observed for bovine and yeast reductases, or Delta 2-decenoyl-CoA, as formed by the E. coli enzyme. To address the stereochemistry of the PDCR catalyzed reaction directly, the reduction product of Delta 2-trans,Delta 4-trans-decadienoyl-CoA was further characterized enzymatically, and the resulting products were analyzed by HPLC (Fig. 6). As expected, the substrate Delta 2-trans,Delta 4-trans-decadienoyl-CoA gave rise to a single peak on HPLC (Fig. 6A). Following addition of both purified PDCR and NADPH, a second peak was detected and was assigned to Delta 3-decenoyl-CoA because this compound did not serve as a substrate for purified crotonase (Delta 2-enoyl-CoA hydratase) (Fig. 6B). However, when purified Delta 3,Delta 2-enoyl-CoA isomerase was added to the reaction mixture, a third compound, presumably Delta 2-decenoyl-CoA, was detected (Fig. 6C). This assignment was verified by the conversion of the putative Delta 2-decenoyl-CoA to 3-hydroxydecanoyl-CoA in the presence of crotonase (Fig. 6D). Thus, the PDCR-catalyzed reduction of Delta 2-trans,Delta 4-trans-decadienoyl-CoAs gives rise to Delta 3-enoyl-CoAs as previously observed for other eukaryotic Delta 2,Delta 4-dienoyl-CoA reductases (25, 27, 28).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 6.   HPLC analysis of the PDCR-catalyzed reaction product. A, HPLC-purified Delta 2-trans,Delta 4-trans-decadienoyl-CoA (8 nmol in 0.2 ml of 60 mM potassium-Pi (pH 7.4)). B, 8 nmol of Delta 2-trans,Delta 4-trans-decadienoyl-CoA in 0.2 ml of 60 mM potassium-Pi (pH 7.4) after incubation for 30 s with 0.1 mM NADPH and 0.2 µg of mouse PDCR in the absence or in the presence of 0.1 unit of crotonase from bovine liver. C, 12 nmol of Delta 2-trans,Delta 4-trans-decadienoyl-CoA in 0.2 ml of 60 mM potassium-Pi (pH 7.4) after incubation for 30 s with 0.1 mM NADPH, 0.13 µg of rat liver Delta 3,Delta 2-enoyl-CoA isomerase, and 0.2 µg of mouse PDCR. D, the mixture contained 0.1 unit of bovine liver crotonase in addition to the components listed for C. Delta 2,4, Delta 2-trans,Delta 4-trans-decadienoyl-CoA; Delta 3, Delta 3-decenoyl-CoA; Delta 2, Delta 2-decenoyl-CoA; 3HO, 3-hydroxydecanoyl-CoA.

As a final test of PDCR activity, the chain length specificity of purified PDCR was assessed with three substrates. The substrates chosen for this study were Delta 2-trans,Delta 4-trans-hexadienoyl-CoA, Delta 2-trans,Delta 4-trans-decadienoyl-CoA, and Delta 2-trans,Delta 4,Delta 7,Delta 10,Delta 13,Delta 16,Delta 19-cis-docosaheptaenoyl-CoA. The apparent Km and Vmax values for Delta 2-trans,Delta 4-trans-decadienoyl-CoA, the best of the three substrates, were determined to be 6 µM and 20 units/mg, respectively (Table I). This Km value is similar to the value of 6.7 µM reported for the same substrate with the bovine reductase (27), whereas the Vmax of 20 units/mg is significantly higher than the value of 3.9 units/mg reported for the bovine enzyme (27). We observed that PDCR was active with substrates having acyl chains of 6 and 22 carbon atoms as well. However, the activities of PDCR toward these Delta 2,Delta 4-dienoyl-CoAs were markedly lower, and the Km values were much higher than the corresponding values obtained with Delta 2-trans,Delta 4-trans-decadienoyl-CoA as the substrate.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Kinetic parameters of recombinant mouse Delta 2,Delta 4-dienoyl-CoA reductase

The PDCR Gene Encodes a Peroxisomal Protein-- The presence of a consensus type-1 peroxisomal targeting signal (Ala-Lys-Leu-COOH) at the C terminus of PDCR strongly suggested that this Delta 2,Delta 4-dienoyl-CoA reductase was in fact a peroxisomal enzyme. To determine whether PDCR was located within peroxisomes, we modified the PDCR cDNA so that it encoded the 10 amino acid c-myc epitope tag at its N terminus and placed it downstream of the cytomegalovirus promoter in the mammalian expression vector pcDNA3. The resulting plasmid, pcDNA3-NmycPDCR, was transfected into human skin fibroblasts. Three days later, the transfected cells were processed for double indirect immunofluorescence microscopy using antibodies specific for the c-myc epitope tag, and for the cytoplasmically exposed C-terminal tail of PMP70, an integral peroxisomal membrane protein (30). Following permeabilization of all cellular compartments, we observed that NmycPDCR colocalized with PMP70 to discrete, punctate structures characteristic of peroxisomes (Fig. 7, A and B). To determine whether NmycPDCR was transported into the peroxisome lumen, we repeated these experiments under differential permeabilization conditions that allow detection of proteins on the outer surface of peroxisome but not in the peroxisome lumen (Fig. 7, C and D) (31). The inability to detect NmycPDCR under these conditions suggested that the protein was inside the peroxisome membrane, whereas the detection of cytosolic tail of PMP70 confirmed that the antibodies did detect cytoplasmically exposed antigens. Similar results were observed for the prototypic peroxisomal enzyme marker, catalase, thereby reaffirming the validity of the differential permeabilization protocol (Fig. 7, E and F).


View larger version (84K):
[in this window]
[in a new window]
 
Fig. 7.   PDCR is a peroxisomal matrix protein. Human skin fibroblasts expressing the Nmyc-PDCR cDNA were processed for double indirect immunofluorescence after permeabilization with 1% Triton X-100. The subcellular distribution of Nmyc-PDCR was examined using anti-myc (A) and anti-PMP70 (B) antibodies. Additional Nmyc-PDCR expressing cells were permeabilized with 25 µg/ml digitonin and were stained with anti-myc (C) and anti-PMP70 (D) antibodies. Cells permeabilized with 25 µg/ml digitonin were also stained with anti-catalase (E) and anti-PMP70 (F) antibodies. Double indirect immunofluorescence was used to examine the distribution of Nmyc-PDCR in pex10-deficient PBD100 cells (permeabilized with 1% Triton X-100) and again with anti-myc (G) and anti-PMP70 (H) antibodies. Bar, 25 µm.

The hypothesis that PDCR is a peroxisomal matrix protein predicts that it should accumulate in the cytoplasm of cells that have a specific defect in matrix protein import. Zellweger syndrome is a lethal human disorder characterized by defects in peroxisomal matrix protein import and is caused by defects in any of at least 12 different genes, all of which play roles in peroxisome biogenesis. Previous studies have established that the cell line PBD100, which was derived from a Zellweger syndrome patient and has inactivating mutations in the PEX10 gene, is unable to import peroxisomal matrix proteins but has no apparent defect in the import of peroxisomal membrane proteins (20). We transfected PBD100 cells with pcDNA3-NmycPDCR and processed these cells for double indirect immunofluorescence, again using antibodies specific for the c-myc epitope tag and for PMP70 (Fig. 7, G and H). The cytoplasmic accumulation of NmycPDCR in these cells, even though they are able to import PMP70 into the peroxisome membrane, supports the hypothesis that PDCR is a peroxisomal matrix protein.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The work presented here describes the first molecular characterization of a mammalian peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase. The mouse cDNA encoding this enzyme (PDCR) was identified on the basis of its potential to encode a protein highly similar to S. cerevisiae Sps19p. Enzymatic characterization of PDCR demonstrated that this enzyme has significant, intrinsic Delta 2,Delta 4-dienoyl-CoA reductase activity and that the product of its action on Delta 2-trans,Delta 4-trans-decadienoyl-CoA was Delta 3-decenoyl-CoA. Thus the catalytic mechanism of PDCR can be assumed to be analogous to other eukaryotic Delta 2,Delta 4-dienoyl-CoA reductases, which have previously been shown to reduce Delta 2,Delta 4-dienoyl-CoAs to Delta 3-enoyl-CoAs (25, 27, 28). We observed that mouse PDCR displays a substrate preference for Delta 2-trans,Delta 4-trans-decadienoyl-CoA over both Delta 2-trans,Delta 4-trans-hexadienoyl-CoA and Delta 2-trans,Delta 4,Delta 7,Delta 10,Delta 13,Delta 16,Delta 19-cis-docosaheptaenoyl-CoA based on the ratio of the observed Vmax and Km constants for these substrates. The observed preference for Delta 2-trans,Delta 4-trans-decadienoyl-CoA likely reflects the cellular role of PDCR in peroxisomal beta -oxidation, namely in the oxidation of long and very long chain fatty acids that contain unsaturations near the middle of the acyl chain (1). Furthermore the observed activity of PDCR on Delta 2-trans,Delta 4,Delta 7,Delta 10,Delta 13,Delta 16,Delta 19-cis-docosaheptaenoyl-CoA is consistent with the established role of peroxisomes in the metabolism of complex, very long chain, polyunsaturated fatty acids such as arachidonic acid and prostaglandins (1).

Using immunofluorescence microscopy we observed that mouse PDCR is targeted to the peroxisomal lumen. This experimental observation of peroxisomal localization is consistent with several lines evidence presented here and elsewhere. First, the presence of the C-terminal sequence Ala-Lys-Leu-COOH in PDCR suggested that this enzyme would be targeted efficiently to peroxisomes. This sequence represents a consensus match to the type-1 peroxisomal targeting signal, an obligatory C-terminal tripeptide motif that is present on the vast majority of peroxisomal matrix proteins (32). Second, we observed a distinct accumulation of PDCR in the cytoplasm of skin fibroblasts derived from a PEX10-deficient Zellweger syndrome patient. The molecular defects in these cells have been characterized at both the genetic and protein level, and it is well established that these cells are deficient in peroxisomal matrix protein import specifically (20). Finally, it has been reported previously that a homotetrameric Delta 2,Delta 4-dienoyl-CoA reductase isolated from rat liver peroxisomes has a subunit molecular mass of approximately 33,000 Da (24). Based on the deduced protein sequence of PDCR, the calculated molecular mass of this novel enzyme is predicted to be 31,298 Da. Thus, the subunit mass of mouse PDCR is in good agreement with that of an orthologous enzyme isolated from peroxisomes of a highly related species.

Mammalian cells contain differentially compartmentalized pathways for the beta -oxidation of fatty acids and the chemical details of the individual steps in both mitochondrial and peroxisomal pathways appear highly similar. For example, both systems require the action of the auxiliary enzymes shown in Fig. 1 to completely oxidize unsaturated fatty acids. Although the enzymatic steps involved in metabolizing Delta 2,Delta 4-dienoyl-CoA intermediates are relatively well understood, the presence of two distinct shunts for degrading Delta 2,Delta 5-dienoyl-CoAs raises questions as to which pathway is responsible for the main flux of carbon skeletons arising from such intermediates. Recent studies on the mitochondrial metabolism of Delta 2-trans,Delta 5-cis-octenoyl-CoA suggest that the hydratase/isomerase shunt handles a majority of the metabolic flux for these intermediates (33). A corollary to this finding is that the reductase-dependent pathway is responsible for maintaining coenzyme A homeostasis in the presence of the unavoidable and possibly deleterious action of Delta 3,Delta 2-enoyl-CoA isomerase on Delta 2,Delta 5-dienoyl-CoAs (Fig. 1) (33). Currently there is no report in the literature that addresses questions of metabolic flux for peroxisomal Delta 2,Delta 5-dienoyl-CoAs. Thus, an assessment of these issues is needed to elaborate our general understanding of peroxisomal unsaturated fatty acid metabolism.

These molecular studies of mouse peroxisomal Delta 2,Delta 4-dienoyl-CoA reductase complete the preliminary characterization of the known auxiliary enzymes of mammalian peroxisomal beta -oxidation. The significance of these studies is underscored by the well established observation that defects in peroxisomal fatty acid metabolism are directly linked to lethal inherited human disorders (34). As of this report four genetically distinct complementation groups of these peroxisomal disorders have been described (34). Although two complementation groups are attributable to defects in acyl-CoA oxidase and the D-specific multifunctional enzyme, the precise enzymatic deficiency in the remaining complementation groups is unknown.2 Because Delta 2,Delta 4-dienoyl-CoA reductase activity is required for complete oxidation of all Delta 2,Delta 4-dienoyl-CoAs, as well as a portion of Delta 2,Delta 5-dienoyl-CoAs, the human form of PDCR represents a candidate disease gene for these disorders. In addition to these uncharacterized complementation groups of peroxisomal fatty acid oxidation deficiency, there also exist reports of a lethal human deficiency in Delta 2,Delta 4-dienoyl-CoA reductase (35, 36). Interestingly, the molecular basis of this deficiency has yet to be resolved. Although one group suggested that the defect lies in a mitochondrial Delta 2,Delta 4-dienoyl-CoA reductase (35), no report describing patient mutations in a gene encoding a mitochondrial Delta 2,Delta 4-dienoyl-CoA reductase exists in the literature, and the possibility that this deficiency is peroxisome-associated has not been examined.

    ACKNOWLEDGEMENTS

We thank Daniel Warren and Jacob Jones for assistance with the immunofluorescence studies.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants DK45787 and HD10981 (to S. J. G.) and by United States Public Health Service Grants HL30847 from the NHLBI, National Institutes of Health (to H. S.) and RR03060 to Research Centers of Minority Institutions.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ These authors contributed equally to this work.

parallel To whom correspondence should be addressed: Dept. of Biological Chemistry, The Johns Hopkins University School of Medicine, 725 N. Wolfe St., Baltimore, MD 21205. Tel.: 410-955-3085; Fax: 410-955-0215; E-mail: stephen.Gould@qmail.bs.jhu.edu.

2 R. J. A. Wanders, personal communication.

    ABBREVIATIONS

The abbreviations used are: EST, expressed sequence tag; HPLC, high pressure liquid chromatography.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Kunau, W.-H., Dommes, V., and Schulz, H. (1995) Prog. Lipid Res. 34, 267-342[CrossRef][Medline] [Order article via Infotrieve]
2. Kunau, W.-H., and Dommes, P. (1978) Eur. J. Biochem. 91, 533-544[Medline] [Order article via Infotrieve]
3. Stoffel, W., and Caesar, H. (1965) Hoppe-Seyler's Z. Physiol. Chem. 341, 76-83[Medline] [Order article via Infotrieve]
4. Smeland, T. E., Nada, M., Cuebas, D., and Schulz, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6673-6677[Abstract/Free Full Text]
5. He, X.-Y., Shoukry, K., Chu, C., Yang, J., Sprecher, H., and Schulz, H. (1995) Biochem. Biophys. Res. Comm. 215, 15-22[CrossRef][Medline] [Order article via Infotrieve]
6. Palosaari, P. M., and Hiltunen, J. K. (1990) J. Biol. Chem. 265, 2446-2449[Abstract/Free Full Text]
7. Filppula, S. A., Yagi, A. I., Kilpelainen, S. H., Novikov, D., Fitzpatrick, D. R., Vihinen, M., Valle, D., and Hiltunen, J. K. (1998) J. Biol. Chem. 273, 349-355[Abstract/Free Full Text]
8. Hirose, A., Kamijo, K., Osumi, T., Hashimoto, T., and Mizugaki, M. (1990) Biochim. Biophys. Acta 1049, 346-349[Medline] [Order article via Infotrieve]
9. Koivuranta, K. T., Hakkola, E. H., and Hiltunen, J. K. (1994) Biochem. J. 304, 787-792
10. Kozak, M. (1989) J. Cell Biol. 108, 229-241[Abstract/Free Full Text]
11. Kozak, M. (1992) Annu. Rev. Cell Biol. 8, 197-225[CrossRef]
12. Grant, S. G., Jessee, J., Bloom, F. R., and Hanahan, D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4645-4649[Abstract/Free Full Text]
13. Jones, J. M., Nau, K., Geraghty, M. T., Erdmann, R., and Gould, S. J. (1999) J. Biol. Chem. 274, 9216-9223[Abstract/Free Full Text]
14. Geisbrecht, B. V., Zhu, D., Schulz, K., Nau, K., Morrell, J. C., Geraghty, M., Schulz, H., Erdmann, R., and Gould, S. J. (1998) J. Biol. Chem. 273, 33184-33191[Abstract/Free Full Text]
15. Steinman, H., and Hill, R. L. (1975) Methods Enzymol. 35, 136-151[Medline] [Order article via Infotrieve]
16. Palosaari, P. M., Kilponen, J. M., Sormunen, R. T., Hassinen, I. E., and Hiltunen, J. K. (1990) J. Biol. Chem. 265, 3347-3353[Abstract/Free Full Text]
17. Cuebas, D., and Schulz, H. (1982) J. Biol. Chem. 257, 14140-14144[Abstract/Free Full Text]
18. Luo, M. J., He, X.-Y., Sprecher, H., and Schulz, H. (1993) Arch. Biochem. Biophys. 304, 266-271[CrossRef][Medline] [Order article via Infotrieve]
19. Slawecki, M., Dodt, G., Steinberg, S., Moser, A. B., Moser, H. W., and Gould, S. J. (1995) J. Cell Sci. 108, 1817-1829[Abstract]
20. Warren, D. S., Morrell, J. C., Moser, H. W., Valle, D., and Gould, S. J. (1998) Am. J. Hum. Genet. 63, 347-359[CrossRef][Medline] [Order article via Infotrieve]
21. Gärtner, J., Moser, H., and Valle, D. (1992) Nat. Genet. 1, 16-23[CrossRef][Medline] [Order article via Infotrieve]
22. Hiltunen, J. K., Karki, T., Hassinen, I. E., and Osmundsen, H. (1986) J. Biol. Chem. 261, 16484-16493[Abstract/Free Full Text]
23. Dommes, V., Baumgart, C., and Kunau, W.-H. (1981) J. Biol. Chem. 256, 8259-8262[Abstract/Free Full Text]
24. Kimura, C., Kondo, A., Koeda, N., Yamanaka, H., and Mizugaki, M. (1984) J. Biochem. 96, 1463-1469[Abstract/Free Full Text]
25. Gurvitz, A., Rottensteiner, H., Kilpelainen, S. H., Hartig, A., Hiltunen, J. K., Binder, M., Dawes, I. W., and Hamilton, B. (1997) J. Biol. Chem. 272, 22140-22147[Abstract/Free Full Text]
26. Gould, S. J., Keller, G. A., Hosken, N., Wilkinson, J., and Subramani, S. (1989) J. Cell Biol. 108, 1657-1664[Abstract/Free Full Text]
27. Dommes, V., and Kunau, W.-H. (1984) J. Biol. Chem. 259, 1781-1788[Abstract/Free Full Text]
28. Mizugaki, M., Kimura, C., Kondo, A., Kawaguchi, A., Okuda, S., and Yamanaka, H. (1984) J. Biochem. (Tokyo) 95, 311-317[Abstract/Free Full Text]
29. Mizugaki, M., Kimura, C., Nishimaki, T., Yamamoto, H., Sagi, M., Nishimura, S., and Yamanaka, H. (1982) J. Biochem. (Tokyo) 92, 1671-1674[Abstract/Free Full Text]
30. Kamijo, K., Taketani, S., Yokata, S., Osumi, T., and Hashimoto, T. (1990) J. Biol. Chem. 265, 4534-4540[Abstract/Free Full Text]
31. Swinkels, B. W., Gould, S. J., Bodnar, A. G., Rachubinski, R. A., and Subramani, S. (1991) EMBO J. 10, 3255-3262[Medline] [Order article via Infotrieve]
32. Subramani, S. (1993) Annu. Rev. Cell Biol. 9, 445-478[CrossRef]
33. Shoukry, K., and Schulz, H. (1998) J. Biol. Chem. 273, 6892-6899[Abstract/Free Full Text]
34. Wanders, R. J., Jansen, G., van Roermund, C. W., Denis, S., Schutgens, R. B., and Jakobs, B. S. (1996) Ann. N. Y. Acad. Sci. 804, 450-460[CrossRef][Medline] [Order article via Infotrieve]
35. Roe, C. R., Millington, D. S., Norwood, D. L., Kodo, N., Sprecher, H., Mohammed, B. D., Nada, M., Schulz, H., and McVie, R. (1990) J. Clin. Invest. 85, 1703-1707
36. Kimura, M., and Yamaguchi, S. (1998) Ryoikibetsu Shokogun Shirizu. 18, 411-413


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
M. S. Alphey, W. Yu, E. Byres, D. Li, and W. N. Hunter
Structure and Reactivity of Human Mitochondrial 2,4-Dienoyl-CoA Reductase: ENZYME-LIGAND INTERACTIONS IN A DISTINCTIVE SHORT-CHAIN REDUCTASE ACTIVE SITE
J. Biol. Chem., January 28, 2005; 280(4): 3068 - 3077.
[Abstract] [Full Text] [PDF]


Home page
Plant Physiol.Home page
S. Reumann, C. Ma, S. Lemke, and L. Babujee
AraPerox. A Database of Putative Arabidopsis Proteins from Plant Peroxisomes
Plant Physiology, September 1, 2004; 136(1): 2587 - 2608.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
I. Shechter, P. Dai, L. Huo, and G. Guan
IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells
J. Lipid Res., November 1, 2003; 44(11): 2169 - 2180.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. Ferdinandusse, S. Denis, G. Dacremont, and R. J. A. Wanders
Studies on the metabolic fate of n-3 polyunsaturated fatty acids
J. Lipid Res., October 1, 2003; 44(10): 1992 - 1997.
[Abstract] [Full Text] [PDF]